Our Work

People with Type 1 diabetes (PWT1) in Europe (EU) and the United States (USA) generally have similar access to diabetes technologies. So how do their health outcomes compare? dQ&A’s work shows that even with similar treatment plans, differing regional factors influencing diabetes management — such as obesity levels and the cost and accessibility of healthcare — potentially affect patient wellness.

Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.

dQ&A is announcing the availability of new data collected this quarter from ten thousand people with diabetes in the USA, Canada and seven EU countries.